Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiplatelet and rivaroxaban therapy in coronary artery ectasia
IRCT20210110049984N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of rivaroxaban, aspirin and clopidogrel in Coronary artery ectasia (CAE) (4 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoints: myocardial infarction, hemorrhagic stroke and 3 more. Started Sep 2021; status: completed.
02
Drugs
rivaroxabanaspirinclopidogrel
03
Conditions
Coronary artery ectasia (CAE)
Beyond the preview
Go deeper on IRCT20210110049984N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210110049984N1.